i The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study was initiated in July 1998. Enrollment was suspended at the second interim analysis in June 2000 because Xigris demonstrated a significant survival benefit that exceeded the prospectively set stopping rules. Analysis indicated a statistically significant 29% relative reduction in risk of death among high-risk (APACHE II score greater or equal to 25) patients (P=0.0002). In these patients, survival rates were 69% for Xigris patients, compared to 56% for standard therapy patients at 28 days. The difference in survival was sustained through 2.5 years of follow-up.
ii Angus DC et al. Crit Care Med 2001; 29,: 1303-10
iii Davies A et al. A European estimate of the burden of disease in ICU. In preparation.
iv Bone RC et al. Chest 1992; 101:1644-55
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)
Web site: http://www.lilly.com
http://www.Xigris.com
Joedy Isert of Eli Lilly and Company, +1-317-276-5592, or cell, +1-317-997-8544, /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO , PRN Photo Desk, photodesk@prnewswire.com